questionsmedicales.fr
Facteurs biologiques
Protéines et peptides de signalisation intercellulaire
Éphrines
Éphrine A3
Éphrine A3 : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Éphrine A3 : Questions médicales les plus fréquentes",
"headline": "Éphrine A3 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Éphrine A3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-21",
"dateModified": "2025-02-15",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Éphrine A3"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Éphrines",
"url": "https://questionsmedicales.fr/mesh/D036342",
"about": {
"@type": "MedicalCondition",
"name": "Éphrines",
"code": {
"@type": "MedicalCode",
"code": "D036342",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Éphrine A3",
"alternateName": "Ephrin-A3",
"code": {
"@type": "MedicalCode",
"code": "D036384",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Elena B Pasquale",
"url": "https://questionsmedicales.fr/author/Elena%20B%20Pasquale",
"affiliation": {
"@type": "Organization",
"name": "Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. elenap@sbpdiscovery.org."
}
},
{
"@type": "Person",
"name": "Katsuaki Ieguchi",
"url": "https://questionsmedicales.fr/author/Katsuaki%20Ieguchi",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan. kieguchi@twmu.ac.jp."
}
},
{
"@type": "Person",
"name": "Yoshiro Maru",
"url": "https://questionsmedicales.fr/author/Yoshiro%20Maru",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan. maru.yoshiro@twmu.ac.jp."
}
},
{
"@type": "Person",
"name": "Stamatios Theocharis",
"url": "https://questionsmedicales.fr/author/Stamatios%20Theocharis",
"affiliation": {
"@type": "Organization",
"name": "First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 157 72 Athens, Greece."
}
},
{
"@type": "Person",
"name": "Liu Yang",
"url": "https://questionsmedicales.fr/author/Liu%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Department of Ophthalmology, Peking University First Hospital, Beijing, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Wikipedia on the CompTox Chemicals Dashboard: Connecting Resources to Enrich Public Chemical Data.",
"datePublished": "2022-10-10",
"url": "https://questionsmedicales.fr/article/36215146",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.jcim.2c00886"
}
},
{
"@type": "ScholarlyArticle",
"name": "Using electronic medical record data to establish and monitor the distribution of refractive errors",
"datePublished": "2022-10-08",
"url": "https://questionsmedicales.fr/article/36220741",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.optom.2022.09.001"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prediction Model and Data Simulation of Sports Performance Based on the Artificial Intelligence Algorithm.",
"datePublished": "2022-10-07",
"url": "https://questionsmedicales.fr/article/36248943",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/7238789"
}
},
{
"@type": "ScholarlyArticle",
"name": "Towards More Efficient Data Valuation in Healthcare Federated Learning using Ensembling.",
"datePublished": "2022-10-07",
"url": "https://questionsmedicales.fr/article/36745141",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/978-3-031-18523-6_12"
}
},
{
"@type": "ScholarlyArticle",
"name": "Update on the clinical trial landscape: analysis of ClinicalTrials.gov registration data, 2000-2020.",
"datePublished": "2022-10-06",
"url": "https://questionsmedicales.fr/article/36203212",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13063-022-06569-2"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Éphrines",
"item": "https://questionsmedicales.fr/mesh/D036342"
},
{
"@type": "ListItem",
"position": 5,
"name": "Éphrine A3",
"item": "https://questionsmedicales.fr/mesh/D036384"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Éphrine A3 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Éphrine A3",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Éphrine A3",
"description": "Comment diagnostiquer une anomalie d'éphrine A3 ?\nQuels examens sont recommandés pour évaluer l'éphrine A3 ?\nY a-t-il des biomarqueurs associés à l'éphrine A3 ?\nQuels symptômes peuvent indiquer un problème avec l'éphrine A3 ?\nPeut-on utiliser l'imagerie pour évaluer l'éphrine A3 ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Data+Display&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Éphrine A3",
"description": "Quels sont les symptômes d'une dysfonction d'éphrine A3 ?\nL'éphrine A3 est-elle liée à des maladies spécifiques ?\nComment l'éphrine A3 affecte-t-elle le système nerveux ?\nDes troubles comportementaux peuvent-ils être liés à l'éphrine A3 ?\nL'éphrine A3 influence-t-elle le développement cérébral ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Data+Display&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Éphrine A3",
"description": "Peut-on prévenir les troubles liés à l'éphrine A3 ?\nY a-t-il des facteurs environnementaux influençant l'éphrine A3 ?\nComment le mode de vie affecte-t-il l'éphrine A3 ?\nDes conseils nutritionnels peuvent-ils aider ?\nL'éducation prénatale peut-elle prévenir des troubles ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Data+Display&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Éphrine A3",
"description": "Quels traitements ciblent l'éphrine A3 ?\nPeut-on modifier l'expression de l'éphrine A3 ?\nY a-t-il des essais cliniques sur l'éphrine A3 ?\nQuels médicaments peuvent affecter l'éphrine A3 ?\nL'éphrine A3 peut-elle être une cible thérapeutique ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Data+Display&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Éphrine A3",
"description": "Quelles complications peuvent survenir avec l'éphrine A3 ?\nL'éphrine A3 est-elle impliquée dans des cancers ?\nDes troubles cognitifs peuvent-ils être des complications ?\nComment les complications sont-elles gérées ?\nY a-t-il des risques de récidive avec l'éphrine A3 ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Data+Display&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Éphrine A3",
"description": "Quels sont les facteurs de risque pour l'éphrine A3 ?\nL'hérédité joue-t-elle un rôle dans les troubles d'éphrine A3 ?\nLes toxines environnementales affectent-elles l'éphrine A3 ?\nLe stress peut-il influencer l'éphrine A3 ?\nY a-t-il des prédispositions génétiques pour l'éphrine A3 ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Data+Display&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie d'éphrine A3 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de tissus peuvent être utilisés pour détecter des anomalies."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour évaluer l'éphrine A3 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'immunohistochimie et la PCR sont souvent utilisés pour évaluer l'expression de l'éphrine A3."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à l'éphrine A3 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éphrine A3 elle-même peut servir de biomarqueur dans certaines pathologies neurologiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec l'éphrine A3 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles neurologiques ou des anomalies de développement peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour évaluer l'éphrine A3 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie cérébrale peut aider à visualiser des anomalies associées à des dysfonctionnements de l'éphrine A3."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une dysfonction d'éphrine A3 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des troubles cognitifs, des problèmes de coordination et des retards de développement."
}
},
{
"@type": "Question",
"name": "L'éphrine A3 est-elle liée à des maladies spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies d'éphrine A3 sont associées à des maladies neurodégénératives et des cancers."
}
},
{
"@type": "Question",
"name": "Comment l'éphrine A3 affecte-t-elle le système nerveux ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle joue un rôle dans la formation des synapses et la plasticité neuronale, influençant le comportement."
}
},
{
"@type": "Question",
"name": "Des troubles comportementaux peuvent-ils être liés à l'éphrine A3 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements de l'éphrine A3 peuvent entraîner des troubles du comportement."
}
},
{
"@type": "Question",
"name": "L'éphrine A3 influence-t-elle le développement cérébral ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est essentielle pour le développement normal des circuits neuronaux dans le cerveau."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés à l'éphrine A3 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par une détection précoce et une intervention dans les cas à risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux influençant l'éphrine A3 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux comme la nutrition et les toxines peuvent influencer son expression."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie affecte-t-il l'éphrine A3 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut favoriser une expression normale de l'éphrine A3 et réduire les risques."
}
},
{
"@type": "Question",
"name": "Des conseils nutritionnels peuvent-ils aider ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée riche en nutriments peut soutenir la santé neuronale et l'éphrine A3."
}
},
{
"@type": "Question",
"name": "L'éducation prénatale peut-elle prévenir des troubles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation prénatale sur les risques environnementaux peut aider à prévenir des troubles liés à l'éphrine A3."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent l'éphrine A3 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des médicaments ciblant les voies de signalisation peuvent être envisagés."
}
},
{
"@type": "Question",
"name": "Peut-on modifier l'expression de l'éphrine A3 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des approches pharmacologiques peuvent moduler l'expression de l'éphrine A3 dans certaines conditions."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques sur l'éphrine A3 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des essais cliniques sont en cours pour évaluer des traitements ciblant l'éphrine A3 dans diverses pathologies."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent affecter l'éphrine A3 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments anticancéreux et neuroprotecteurs peuvent influencer l'activité de l'éphrine A3."
}
},
{
"@type": "Question",
"name": "L'éphrine A3 peut-elle être une cible thérapeutique ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en raison de son rôle dans diverses maladies, elle est considérée comme une cible thérapeutique potentielle."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'éphrine A3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques et des troubles de développement peuvent survenir en cas d'anomalies."
}
},
{
"@type": "Question",
"name": "L'éphrine A3 est-elle impliquée dans des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies d'éphrine A3 sont associées à certains types de cancers, notamment le gliome."
}
},
{
"@type": "Question",
"name": "Des troubles cognitifs peuvent-ils être des complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements de l'éphrine A3 peuvent entraîner des troubles cognitifs sévères."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications implique des traitements symptomatiques et des interventions ciblées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de récidive avec l'éphrine A3 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des risques de récidive peuvent exister dans les cas de cancers associés à des anomalies d'éphrine A3."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour l'éphrine A3 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs génétiques, environnementaux et le mode de vie peuvent influencer le risque d'anomalies."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans les troubles d'éphrine A3 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de troubles neurologiques peuvent augmenter le risque d'anomalies."
}
},
{
"@type": "Question",
"name": "Les toxines environnementales affectent-elles l'éphrine A3 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certaines toxines peut perturber l'expression de l'éphrine A3."
}
},
{
"@type": "Question",
"name": "Le stress peut-il influencer l'éphrine A3 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter la signalisation de l'éphrine A3 et la santé neuronale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques pour l'éphrine A3 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines variations génétiques peuvent prédisposer les individus à des troubles liés à l'éphrine A3."
}
}
]
}
]
}
The online encyclopedia Wikipedia aggregates a large amount of data on chemistry, encompassing well over 20,000 individual Wikipedia pages and serves the general public as well as the chemistry commun...
To establish the baseline distribution of refractive errors and associated factors amongst a population that attended primary care optometry clinics....
Retrospective cross sectional cohort study of electronic medical records (EMR)....
Electronic medical record data was extracted from forty optometry clinics, representing a mix of urban and rural areas in Ireland. The analysis was confined to demographic and clinical data gathered o...
153,598 clinic records were eligible for analysis. Refractive errors ranged from -26.00 to +18.50 D. Myopia was present in 32.7%, of which high myopia represented 2.4%, hyperopia in 40.1%, astigmatism...
Although EMR data is not representative of the population as a whole, it is likely to provide a reasonable representation of the distribution of clinically significant (symptomatic) refractive errors....
There is still a certain deviation between the current artificial intelligence technology and the traditional learning mode, which makes it unable to be effectively applied in teaching and learning. T...
Federated Learning (FL) wherein multiple institutions collaboratively train a machine learning model without sharing data is becoming popular. Participating institutions might not contribute equally -...
The clinical trial landscape has evolved over the last two decades, shaped by advances in therapeutics and drug development and innovation in trial design and methods. The tracking of such changes bec...
We analyzed data from the publicly available Clinical Trials Transformation Initiative Aggregate Analysis of ClinicalTrials.gov (AACT) database, focusing on trials (interventional studies) started bet...
There were 274,043 registered interventional studies (trials) included in the analysis. Most trials were reported as randomized (65%); single site (60%); parallel-group (56%); funded by other sources ...
Clinical trial registration has transformed how trial information is accessed, disseminated, and used. As clinical trials evolve and regulations change, trial registries, including ClinicalTrials.gov,...
With the development of modern Internet technology, the health assessment model based on computer technology has gradually become a research hotspot. In the process of studying the health level of res...
Artificial intelligence allowing data-driven prediction of physicochemical properties of polymers is rapidly emerging as a powerful tool for advancing material science. Here, we developed a methodolog...
To assess the accuracy of probabilistic deep learning models to discriminate normal eyes and eyes with glaucoma from fundus photographs and visual fields....
Algorithm development for discriminating normal and glaucoma eyes using data from multicenter, cross-sectional, case-control study....
Fundus photograph and visual field data from 1,655 eyes of 929 normal and glaucoma subjects to develop and test deep learning models and an independent group of 196 eyes of 98 normal and glaucoma pati...
Accuracy and area under the receiver-operating characteristic curve (AUC)....
Fundus photographs and OCT images were carefully examined by clinicians to identify glaucomatous optic neuropathy (GON). When GON was detected by the reader, the finding was further evaluated by anoth...
The AUC of the deep learning model in detecting glaucoma from fundus photographs, visual fields, and combined modalities using development dataset were 0.90 (95% confidence interval: 0.89-0.92), 0.89 ...
Probabilistic deep learning models can detect glaucoma from multi-modal data with high accuracy. Our findings suggest that models based on combined visual field and fundus photograph modalities detect...
Research in person and face perception has broadly focused on group-level consensus that individuals hold when making judgments of others (e.g., "X type of face looks trustworthy"). However, a growing...
Climate change is difficult to connect with personally, because people only regard the phenomenon as important if it becomes a perceived threat to themselves. Arguments like statistics and policy deba...